RecruitingNCT06988618
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Sponsor
Galderma R&D
Enrollment
600 participants
Start Date
Aug 11, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
- Participants greater than or equal to (>=) 18 years of age.
- Participants who signed the written informed consent form (ICF).
Exclusion Criteria4
- Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
- Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
- Participants who received nemolizumab previously.
- Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(51)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06988618
Related Trials
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952121 locations
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965121 locations
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
NCT0629305314 locations
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
NCT0608762711 locations
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
NCT067791361 location